ACM
JSPR icon

ADAR1 Capital Management’s Jasper Therapeutics JSPR Stock Holding History

ADAR1 Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9K Hold
140,000
– – ﹤0.01% 270
2026
Q1 		$123K Hold
140,000
– – 0.01% 280
2025
Q4 		$256K Buy
+140,000
New +$281K 0.02% 218
2024
Q4 		– Sell
-15,816
Closed -$297K – 258
2024
Q3 		$297K Buy
+15,816
New +$315K 0.05% 142
2024
Q2 		– Sell
-2,406
Closed -$70.6K – 296
2024
Q1 		$70.6K Buy
+2,406
New +$42.7K 0.02% 164

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's JSPR Position: Q2 2026 in Review

ADAR1 Capital Management held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 140,000 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

ADAR1 Capital Management first reported a position in JSPR in Q1 2024 and has held it in 5 quarters since. The position peaked at $297K in Q3 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • ADAR1 Capital Management held 140,000 shares of Jasper Therapeutics worth $58.9K as of Q2 2026.
  • ADAR1 Capital Management left its Jasper Therapeutics share count unchanged in Q2 2026.
  • Jasper Therapeutics made up ﹤0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #270 holding.
  • ADAR1 Capital Management first reported a position in Jasper Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • ADAR1 Capital Management's Jasper Therapeutics position peaked at $297K in Q3 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.